Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib
Amin Aalipour, Ranjana H. Advani
Therapeutic Advances in Hematology (2014) Vol. 5, Iss. 4, pp. 121-133
Open Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
Chengyuan Liang, Danni Tian, Xiaodong Ren, et al.
European Journal of Medicinal Chemistry (2018) Vol. 151, pp. 315-326
Closed Access | Times Cited: 155
Targets for Ibrutinib Beyond B Cell Malignancies
Anna Berglöf, Abdulrahman Hamasy, Stephan Meinke, et al.
Scandinavian Journal of Immunology (2015) Vol. 82, Iss. 3, pp. 208-217
Open Access | Times Cited: 118
Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis
Amelia Bercusson, Thomas Colley, Anand Shah, et al.
Blood (2018) Vol. 132, Iss. 18, pp. 1985-1988
Open Access | Times Cited: 105
Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells
Niraj Shenoy, Tushar D. Bhagat, E. Nieves, et al.
Blood Cancer Journal (2017) Vol. 7, Iss. 7, pp. e587-e587
Open Access | Times Cited: 100
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Bhawana George, Sayan Mullick Chowdhury, Amber Hart, et al.
Cancers (2020) Vol. 12, Iss. 5, pp. 1328-1328
Open Access | Times Cited: 90
The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia
Sílvia Xargay‐Torrent, Mònica López‐Guerra, Laia Rosich, et al.
Oncotarget (2015) Vol. 6, Iss. 26, pp. 22734-22749
Open Access | Times Cited: 66
Treatment of Diffuse Large B-Cell Lymphoma
Kana Miyazaki
Journal of Clinical and Experimental Hematopathology (2016) Vol. 56, Iss. 2, pp. 79-88
Open Access | Times Cited: 64
HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis
Jin Kyun Park, Joo-Yun Byun, Ji Ah Park, et al.
Arthritis Research & Therapy (2016) Vol. 18, Iss. 1
Open Access | Times Cited: 61
A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions
Faroogh Marofi, Heshu Sulaiman Rahman, Muhammad Harun Achmad, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 48
BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses
Mohammad Althubiti, Miran Rada, Jesvin Samuel, et al.
Cancer Research (2016) Vol. 76, Iss. 18, pp. 5405-5414
Open Access | Times Cited: 53
Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications.
Mahsa Mohseni, Hasan Uludağ, Joseph Brandwein
PubMed (2018) Vol. 8, Iss. 4, pp. 29-56
Closed Access | Times Cited: 47
Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis
Neeta Garg, Elizabeth Jordan Padron, Kottil Rammohan, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 20, pp. 6139-6139
Open Access | Times Cited: 26
A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
Laura Airas, Robert Bermel, Tanuja Chitnis, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 5
Investigational Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis
Peter Norman
Expert Opinion on Investigational Drugs (2016) Vol. 25, Iss. 8, pp. 891-899
Closed Access | Times Cited: 45
Target Specific Inhibition of Protein Tyrosine Kinase in Conjunction With Cancer and SARS-COV-2 by Olive Nutraceuticals
Arabinda Ghosh, Nobendu Mukerjee, Bhavdeep Sharma, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 22
Chemically Induced Hypertension: Antineoplastic Agents Associated with High Blood Pressure
Emily Moss, Anushree C. Shirali
Updates in hypertension and cardiovascular protection (2025), pp. 79-91
Closed Access
Amelioration of age‐related brain function decline by Bruton's tyrosine kinase inhibition
Akang E. Ekpenyong‐Akiba, Marta Poblocka, Mohammad Althubiti, et al.
Aging Cell (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 33
Naturally Occurring Calanolides: Occurrence, Biosynthesis, and Pharmacological Properties Including Therapeutic Potential
Lutfun Nahar, Anupam Das Talukdar, Deepa Nath, et al.
Molecules (2020) Vol. 25, Iss. 21, pp. 4983-4983
Open Access | Times Cited: 31
Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment
Logan Good, Brooke Benner, William E. Carson
Cancer Immunology Immunotherapy (2021) Vol. 70, Iss. 9, pp. 2439-2451
Open Access | Times Cited: 25
BCL10 mutations define distinct dependencies guiding precision therapy for DLBCL
Min Xia, Liron David, Matt Teater, et al.
Cancer Discovery (2022), pp. OF1-OF20
Open Access | Times Cited: 17
Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression
Kana Miyazaki, Motoko Yamaguchi, Hiroshi Imai, et al.
International Journal of Hematology (2015) Vol. 102, Iss. 2, pp. 188-194
Closed Access | Times Cited: 26
Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy
Miran Rada, Zahraa Qusairy, Marta Massip‐Salcedo, et al.
Molecular Cancer Research (2020) Vol. 19, Iss. 4, pp. 549-554
Open Access | Times Cited: 22
Enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system
Fareeaa Ashar, Asif Ansari Shaik Mohammed, Subramanian Selvamuthukumar
PLoS ONE (2024) Vol. 19, Iss. 9, pp. e0310492-e0310492
Open Access | Times Cited: 2
Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study
Mark C. Genovese, Alberto Spindler, Akira Sagawa, et al.
The Journal of Rheumatology (2020) Vol. 48, Iss. 7, pp. 969-976
Closed Access | Times Cited: 18
Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances
Mohammad Hojjat‐Farsangi
Journal of drug targeting (2015) Vol. 24, Iss. 3, pp. 192-211
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top